Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-600-7373
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees13
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions
What is Minerva Neurosciences' stock symbol?
Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."
How were Minerva Neurosciences' earnings last quarter?
Minerva Neurosciences Inc (NASDAQ:NERV) released its quarterly earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.10. View Minerva Neurosciences' Earnings History.
When is Minerva Neurosciences' next earnings date?
What price target have analysts set for NERV?
3 brokers have issued 12-month target prices for Minerva Neurosciences' shares. Their predictions range from $17.00 to $26.00. On average, they expect Minerva Neurosciences' share price to reach $21.67 in the next twelve months. This suggests a possible upside of 427.2% from the stock's current price. View Analyst Price Targets for Minerva Neurosciences.
What is the consensus analysts' recommendation for Minerva Neurosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Minerva Neurosciences.
What are Wall Street analysts saying about Minerva Neurosciences stock?
Here are some recent quotes from research analysts about Minerva Neurosciences stock:
- 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (10/19/2019)
- 2. HC Wainwright analysts commented, "Valuation Our $22 price target for Minerva is based on our sum-of-the-parts NPV valuation based on each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (5/31/2019)
Has Minerva Neurosciences been receiving favorable news coverage?
Media coverage about NERV stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Minerva Neurosciences earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Minerva Neurosciences.
Are investors shorting Minerva Neurosciences?
Minerva Neurosciences saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 2,250,000 shares, an increase of 13.1% from the August 30th total of 1,990,000 shares. Based on an average daily trading volume, of 325,600 shares, the short-interest ratio is presently 6.9 days. Approximately 7.0% of the shares of the stock are sold short. View Minerva Neurosciences' Current Options Chain.
Who are some of Minerva Neurosciences' key competitors?
Some companies that are related to Minerva Neurosciences include Rocket Pharmaceuticals (RCKT), Kura Oncology (KURA), ZIOPHARM Oncology (ZIOP), Vectura Group (VEGPF), NextCure (NXTC), Akorn (AKRX), Homology Medicines (FIXX), Advanz Pharma (CXRXF), Akero Therapeutics (AKRO), OrganiGram (OGI), DiaMedica Therapeutics (DMCAF), MacroGenics (MGNX), Flexion Therapeutics (FLXN), IGM Biosciences (IGMS) and Catalyst Pharmaceuticals (CPRX).
What other stocks do shareholders of Minerva Neurosciences own?
Who are Minerva Neurosciences' key executives?
Minerva Neurosciences' management team includes the folowing people:
- Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 58)
- Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 58)
- Dr. Michael Davidson, Chief Medical Officer (Age 69)
- Mr. Richard Russell, Pres (Age 55)
- Mr. Joseph Reilly, Sr. VP & COO (Age 44)
Who are Minerva Neurosciences' major shareholders?
Minerva Neurosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Meeder Asset Management Inc. (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View Institutional Ownership Trends for Minerva Neurosciences.
Which institutional investors are buying Minerva Neurosciences stock?
NERV stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer and William F Doyle. View Insider Buying and Selling for Minerva Neurosciences.
How do I buy shares of Minerva Neurosciences?
Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Minerva Neurosciences' stock price today?
One share of NERV stock can currently be purchased for approximately $4.11.
How big of a company is Minerva Neurosciences?
Minerva Neurosciences has a market capitalization of $160.41 million. The biopharmaceutical company earns $-50,170,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.View Additional Information About Minerva Neurosciences.
What is Minerva Neurosciences' official website?
How can I contact Minerva Neurosciences?
Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]
MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.
